6 best EDC platforms for Japan PMS studies in 2026

A Japan post-market surveillance study that can't handle booklet data collection or track Kaifu workflows properly doesn't just create operational friction — it puts your PMDA submission timeline at risk and strains already-lean MedTech clinical teams. Viedoc's PMS solution delivers native Japan post-market surveillance capability with built-in booklet data collection, Kaifu process management, and PMDA ERES compliance, all within the same no-code Designer environment your team already uses for global EDC studies. This comparison evaluates six EDC platforms for Japan post-market surveillance studies across regulatory compliance, Japan-specific functionality, study design flexibility, and lean-team usability.

You're running post-market surveillance studies in Japan because regulatory approval requires it — and you need an EDC platform that treats Japan PMS as a first-class workflow, not a workaround built on top of pharma-centric templates. Your clinical affairs team doesn't have bandwidth to manage separate systems for booklet data and progress tracking, and your QA lead won't sign off on a platform that treats PMDA ERES compliance as an afterthought.

Generic EDC platforms built for pharma Phase III trials force you into awkward compromises: manually tracking Kaifu stages outside the system, cobbling together booklet data collection through custom forms that weren't designed for the purpose, or maintaining parallel spreadsheets for progress management because the EDC doesn't understand Japan PMS regulatory requirements. You need a platform that supports booklet data natively, manages the Kaifu review process within the application, and provides PMDA-ready audit trails without requiring your one data manager to become a regulatory expert on top of everything else they're already handling.

Best EDC solutions for Japan PMS: quick comparison

These six eClinical platforms represent the most evaluated options for Japan post-market surveillance studies, reviewed across PMDA regulatory compliance, Japan-specific PMS functionality, study design adaptability, and lean-team operational fit.

1. Viedoc

Viedoc's PMS solution is purpose-built for Japan post-market surveillance studies, offering native booklet data collection, Kaifu process management, progress tracking, and query management — all within a single application that integrates with the same Viedoc Designer environment used for global EDC studies. The platform handles Japan's specific PMS regulatory requirements without requiring parallel systems or manual workarounds, supported by PMDA ERES compliance and full APPI (Japan) data privacy certification.

Viedoc's Japan PMS module sits within the broader Viedoc eClinical suite, meaning medical device companies can manage global clinical studies and Japan post-market surveillance from a unified platform with consistent user training, a single validation envelope, and consolidated vendor management. The no-code Designer approach lets certified data managers configure PMS studies in-house without programmer dependency, while the flexible study workflow adapts to device-specific endpoints, follow-up schedules, and registry structures that don't fit pharma trial templates. Viedoc's EDC software provides the underlying data capture and monitoring infrastructure, extended by the PMS module for Japan-specific regulatory requirements.

Viedoc is ISO 27001, ISO 9001, and SOC 2 Type II certified, with FDA 21 CFR Part 11, ICH-GCP, EMA, EU Annex 11, GDPR, and HIPAA compliance. Japan-specific certifications include PMDA ERES compliance and APPI (Japan) data privacy certification. The platform delivers 99.99% uptime across all hosted environments on Microsoft Azure, with 24/7 customer success support across global offices. Viedoc supports trials in 40+ languages across 75+ countries, with unlimited user seats included in standard study-based licensing.

"Viedoc is a very user friendly interface, easy to understand and navigate through. Because of this the time taken to train for the EDC is minimal to become proficient. It offers customizable study workflow and tailoring it according to trial specification is easy. Good query management feature which maintains data accuracy." — Sanchita V., Data Manager

Verified Proof Points:

• Japan PMS module: Native post-market surveillance functionality with booklet data collection and Kaifu process management
• PMDA compliance: PMDA ERES compliant; APPI (Japan) certified for data privacy
• Study scale: 7,000+ studies run on Viedoc across 75+ countries
• User base: 140,000+ users globally; 30,000+ sites; 1.6 million trial participants
• Uptime: 99.99% platform uptime; hosted on Microsoft Azure
• Language support: Available in 40+ languages
• Pricing: Unlimited user seats; no per-user fees; transparent, study-based licensing
• No-code designer: Studies configured in-house by certified data managers; no vendor-side programmer required
• Compliance: ISO 27001, ISO 9001, SOC 2 Type II certified; FDA 21 CFR Part 11, ICH-GCP, GDPR, HIPAA, EU Annex 11
• Support: 24/7 support across global offices
  

  Launch, manage, and monitor clinical trials faster with intuitive EDC clinical trial software that keeps you compliant and audit ready.

2. Medidata

Medidata offers Rave EDC, the category-leading platform for large pharma Phase II and Phase III clinical trials, with established regulatory track record across FDA, EMA, and PMDA submissions. The platform provides comprehensive data capture, monitoring, and analytics capabilities designed for complex global trial operations, with broad integration to Medidata's clinical cloud suite for RTSM, eTMF, CTMS, and signal detection workflows. Medidata's regulatory compliance coverage includes 21 CFR Part 11, ICH-GCP, and GDPR, with documented use in PMDA submissions, though the platform does not offer a native Japan PMS module and typically requires custom configuration for post-market surveillance workflows that differ from interventional trial structures. Rave EDC targets enterprise pharma and large CROs with established Medidata relationships; implementation timelines and study build complexity reflect the platform's positioning for large-scale, multiregional trials rather than lean MedTech teams managing focused Japan PMS studies.

3. Veeva Vault EDC

Veeva Vault EDC is a cloud-based EDC system integrated within the broader Veeva Vault suite for unified clinical, regulatory, and quality management. The platform targets pharma and biotech sponsors managing late-phase trials with interconnected needs across eTMF, RIM, and quality documents, offering study design, data capture, monitoring, and SDTM export capabilities within a single Veeva ecosystem. Veeva Vault EDC is compliant with FDA 21 CFR Part 11, ICH-GCP, and GDPR, with regulatory submissions across major health authorities including PMDA. The platform does not include a native Japan post-market surveillance module and requires configuration of custom workflows for booklet data collection and Kaifu process tracking. Vault EDC delivers value when organizations are adopting the full Veeva suite; standalone EDC buyers managing Japan PMS studies without broader Vault ecosystem requirements may find the platform's scope and licensing model exceed their operational needs.

4. Oracle Health InForm

Oracle Health offers InForm, a legacy EDC platform with decades of regulatory submission history across FDA, EMA, and PMDA-regulated trials. InForm provides traditional study design, data capture, edit check, and query management capabilities with established validation documentation for 21 CFR Part 11 and ICH-GCP compliance. The platform supports global clinical trials through Oracle's infrastructure but operates on older architectural patterns that typically require vendor-side programmers for study builds and amendments, limiting the in-house agility that lean MedTech teams need for rapid PMS study iterations. InForm does not offer a native Japan PMS module and requires custom development for booklet data workflows and Kaifu process tracking. The platform's market positioning has shifted toward maintenance of existing customer bases rather than competitive pursuit of new MedTech accounts, with limited investment in features tailored to post-market surveillance or device trial workflows outside traditional pharma contexts.

5. Castor EDC

Castor EDC offers a no-code EDC platform focused on academic research, investigator-initiated trials, and early-phase commercial studies. The platform provides straightforward study design, data capture, and reporting capabilities with a user-friendly interface designed for teams without dedicated EDC administrators. Castor EDC is compliant with FDA 21 CFR Part 11, ICH-GCP, and GDPR, with cloud-based deployment on Microsoft Azure. The platform does not include a Japan post-market surveillance module or documented PMDA ERES compliance, and its primary market presence is in Europe and North America rather than the Japan regulatory environment. Castor's positioning targets cost-sensitive and lower-complexity study environments; MedTech companies managing PMDA-regulated post-market surveillance studies with specific booklet data and Kaifu workflow requirements would need to assess whether the platform's feature set and Japan regulatory experience align with their compliance and operational needs.

6. OpenClinica

OpenClinica provides an open-source EDC platform widely used in academic research and cost-sensitive clinical environments where teams have internal IT resources to manage infrastructure and validation. The platform offers core data capture, edit check, and query management capabilities with flexibility to customize workflows through open-source code access. OpenClinica requires organizations to manage their own validation, security infrastructure, and regulatory compliance documentation, which introduces overhead that may exceed the capacity of lean MedTech clinical teams. The platform does not include a native Japan post-market surveillance module, PMDA ERES compliance documentation, or booklet data workflows, and would require custom development to support Kaifu process tracking and Japan-specific regulatory requirements. OpenClinica's value proposition centers on eliminating vendor licensing costs for organizations with dedicated IT staff; medical device companies evaluating EDC platforms for Japan PMS studies should weigh the total cost of ownership including validation, infrastructure, and ongoing maintenance against commercial EDC platforms with native PMS functionality and turnkey regulatory compliance.

What to look for in EDC platforms for Japan post-market surveillance studies

Japan post-market surveillance studies operate under regulatory requirements that differ fundamentally from interventional clinical trials — and the EDC platform you choose must handle these requirements natively, not through workarounds. MedTech teams managing PMS studies need platforms that understand booklet data collection, Kaifu process workflows, and PMDA regulatory expectations without forcing your one data manager to build custom solutions on top of a pharma-centric EDC.

Native Japan PMS regulatory functionality

Japan's PMDA requires specific data structures and workflows for post-market surveillance studies that don't map cleanly to interventional trial templates. Booklet data collection captures structured follow-up information in formats that PMDA inspectors expect to see, while the Kaifu process manages the formal review stages between sites and sponsors that are unique to Japan PMS regulatory requirements. An EDC platform with native Japan PMS functionality handles these workflows as first-class features — booklet data entry, Kaifu stage tracking, and progress management — rather than requiring your team to configure custom forms and track regulatory milestones manually outside the system.

Best-in-class platforms provide PMDA ERES compliance documentation, APPI data privacy certification for handling Japanese patient information, and built-in audit trails structured for PMDA inspections. They integrate booklet data and Kaifu workflows directly into the study design environment so your data manager can configure them using the same tools they use for global EDC studies, reducing training overhead and validation complexity. The platform should generate PMDA-ready reports for booklet data and Kaifu status without requiring export to external spreadsheets.

Without native PMS functionality, you're managing parallel systems — one for clinical data, one for booklet tracking, one for Kaifu review — which fragments your audit trail, multiplies your validation burden, and creates operational risk every time a PMDA inspector asks to see the complete picture.

Study design flexibility for device-specific workflows

Medical device post-market surveillance studies don't follow the fixed visit schedules and endpoint structures that pharma EDC platforms assume. Device PMS studies include long-term follow-up registries, observational cohorts with variable visit windows, and device-specific endpoints (implant performance, procedure complications, long-term safety signals) that require flexible CRF design without forcing device data into drug trial templates.

A platform built for MedTech workflows allows you to configure study-specific visit schedules, adaptive follow-up intervals based on device usage or patient-reported events, and custom endpoints that track device performance metrics alongside clinical outcomes. The no-code design capability must extend to PMS-specific forms — not just interventional trial templates — so your certified data manager can build booklet data CRFs and Kaifu review forms in-house without waiting for vendor programmers to interpret Japan regulatory requirements they may not fully understand.

Platforms that lock you into rigid pharma trial structures force workarounds that create downstream problems: manual tracking of device accountability outside the EDC, spreadsheet-based management of variable follow-up schedules, and custom reports cobbled together because the platform's standard outputs assume fixed-visit drug trials. You need a platform that adapts to device study reality, not one that makes you adapt your study to the platform's limitations.

Lean-team operational efficiency and minimal IT overhead

MedTech clinical affairs teams running Japan PMS studies typically operate with one or two people managing study design, site coordination, data review, and regulatory reporting — you don't have dedicated EDC administrators, and you can't afford platforms that require ongoing vendor support for every amendment or reporting request. Cloud-native deployment eliminates on-premise infrastructure management, while unlimited user seats remove the artificial constraint of per-seat licensing that penalizes you for adding regional monitors or temporary study coordinators.

The platform's design environment must support self-service study builds by certified internal staff, with amendments completed in days rather than vendor-dependent cycles that stretch into weeks. Query management, progress tracking, and data export capabilities need to be accessible through intuitive interfaces that don't require specialist training — because your data manager is also handling site training, monitoring data quality, and preparing PMDA submission packages.

Platforms designed for enterprise pharma operations assume you have dedicated EDC teams, IT staff managing infrastructure, and budgets that absorb per-seat fees as operational overhead. MedTech teams managing focused Japan PMS portfolios need platforms that recognize your reality: lean staff, constrained budgets, and operational models where the same person designing the study is also running it and reporting on it.

Integration capability with progress management and external systems

Japan post-market surveillance studies often require integration with commercial progress management systems that track site enrollment, patient follow-up schedules, and regulatory milestone completion outside the EDC. Your platform must provide documented integration pathways — REST APIs, flat file export/import, or certified connectors — that allow progress data to flow between systems without manual reconciliation every reporting cycle.

Medical device companies also need EDC platforms that integrate with device registries, lab systems for diagnostic data, and imaging platforms for procedure documentation. Integration overhead compounds quickly when you're managing data sources that the EDC vendor didn't anticipate — if every new data stream requires custom development and validation, you're paying integration costs that erode the ROI of the entire eClinical stack.

Best-in-class platforms provide flexible integration architecture with clear documentation, established certification processes for common third-party systems, and sufficient API depth that your IT partner or system integrator can connect new data sources without requiring the EDC vendor to build custom modules. They also support CDISC standards (CDASH templates, SDTM conversion) so data can flow to regulatory submission packages without extensive post-processing.

How to choose the right EDC platform for Japan post-market surveillance studies

Step 1: Confirm PMDA ERES compliance and Japan-specific regulatory readiness

Verify that the platform provides documented PMDA ERES compliance, APPI data privacy certification, and structured audit trail capabilities that meet Japan regulatory expectations. Request validation documentation, inspection readiness packets, and evidence of successful PMDA submissions using the platform for post-market surveillance studies specifically — not just general clinical trial use. Platforms without Japan-specific compliance documentation will require your QA team to fill validation gaps, which delays go-live and increases total cost of ownership.

Step 2: Assess native Japan PMS functionality depth

Evaluate whether the platform handles booklet data collection, Kaifu process workflows, and progress management as native features or whether your team will need to configure custom workarounds. Request a live demonstration of a PMS study build showing how booklet data is structured, how Kaifu review stages are tracked, and how progress management integrates with study operations. If the vendor suggests custom development or third-party add-ons to achieve Japan PMS functionality, you're looking at a platform that treats post-market surveillance as an edge case rather than a supported workflow.

Step 3: Evaluate study design flexibility for device workflows

Test the platform's ability to handle non-pharma study structures: variable follow-up intervals, device-specific endpoints, registry and observational cohort designs, and long-term safety tracking beyond fixed trial completion dates. Ask to see examples of device PMS studies configured in the platform with real CRF designs — not generic demo studies. Platforms optimized for interventional drug trials will struggle with the workflow variations that define medical device post-market surveillance.

Step 4: Scrutinize operational fit for lean MedTech teams

Assess whether the platform's study build model, user licensing structure, and support requirements align with your team's capacity. Confirm that certified internal staff can design, amend, and manage studies without ongoing vendor dependency. Evaluate training requirements: if your data manager needs weeks of specialized training to perform basic study configuration, the platform isn't designed for lean-team operations. Validate that user licensing is unlimited or study-based rather than per-seat, so adding regional monitors or temporary coordinators during high-enrollment periods doesn't trigger unexpected costs.

Step 5: Choose a platform that supports your operational reality

If you're managing focused Japan post-market surveillance portfolios with lean clinical teams, limited IT infrastructure, and regulatory requirements that don't fit pharma trial patterns, Viedoc's PMS solution delivers native Japan PMS functionality with booklet data collection and Kaifu process management built into the same no-code Designer environment used across 7,000+ global studies. The platform provides PMDA ERES compliance, APPI certification, and unlimited user seats with 24/7 support — designed for MedTech operational models where the same team designing the study is also running it. Book a demo or request a proposal and our team will walk you through Japan PMS functionality, study design flexibility, and regulatory readiness in the context of your own device portfolio.

Frequently asked questions

What is the best EDC platform for Japan post-market surveillance studies?

Viedoc's PMS solution is the best EDC platform for Japan post-market surveillance studies, offering native booklet data collection, Kaifu process management, and PMDA ERES compliance within a no-code Designer environment that your data management team can operate independently. Viedoc's Japan PMS module integrates with the broader Viedoc eClinical suite used across 7,000+ studies in 75+ countries, providing consistent training, unified validation, and transparent study-based licensing with unlimited user seats. Medidata Rave EDC is the category benchmark for large pharma Phase III trials but does not include native Japan PMS functionality and operates on longer build timelines with programmer-dependent configuration. Veeva Vault EDC targets organizations adopting the full Veeva suite; standalone EDC buyers managing Japan PMS studies may find the platform's scope exceeds their operational needs.

What regulatory compliance should I look for in an EDC platform for Japan PMS studies?

Look for documented PMDA ERES compliance, APPI (Japan) data privacy certification, and structured audit trails that meet Japan regulatory inspection standards. The platform should provide validation documentation specifically for post-market surveillance workflows — not just general clinical trial compliance — including computer system validation support, electronic signature capability compliant with PMDA requirements, and inspection readiness packets that streamline regulatory audits. FDA 21 CFR Part 11, ICH-GCP, and GDPR compliance are table stakes for global EDC platforms, but Japan PMS studies require the additional layer of PMDA-specific regulatory readiness that not all platforms document clearly.

What is the difference between booklet data collection and standard EDC data capture?

Booklet data collection in Japan post-market surveillance studies captures structured follow-up information in formats defined by PMDA regulatory requirements, typically organized around specific follow-up intervals, device-related events, and safety signal tracking that differ from interventional trial CRFs. Booklet data follows PMDA-specified data dictionaries and reporting structures that inspectors expect to see during regulatory reviews. Standard EDC data capture for clinical trials uses protocol-defined CRFs designed around study visits, endpoints, and adverse event reporting structures that align with interventional study designs. An EDC platform with native Japan PMS functionality handles booklet data as a first-class workflow with built-in templates and regulatory-compliant data structures, rather than requiring custom configuration of standard CRF forms.

What is the Kaifu process in Japan post-market surveillance studies?

The Kaifu process manages the formal review and approval workflow between investigator sites and sponsors for booklet data and study documentation in Japan post-market surveillance studies, reflecting regulatory expectations for documented oversight and data quality assurance specific to PMDA requirements. Kaifu stages track the progression of data through sponsor review, query resolution, and formal approval cycles in a structured audit trail that PMDA inspectors evaluate during regulatory submissions. EDC platforms with native Japan PMS functionality provide built-in Kaifu workflow management with stage tracking, review responsibilities, and automated notifications, eliminating the need to track regulatory review milestones manually in external systems.

Can I use the same EDC platform for global clinical studies and Japan PMS studies?

Yes. Platforms like Viedoc that offer integrated eClinical suites with native Japan PMS modules allow medical device companies to manage global interventional trials and Japan post-market surveillance studies from a unified platform, reducing training overhead, consolidating vendor management, and maintaining consistent validation documentation across your clinical portfolio. Using a single platform with modular PMS functionality eliminates the operational friction of managing separate systems for different study types while preserving the Japan-specific regulatory workflows that PMDA requires. When evaluating platforms for this dual capability, confirm that the Japan PMS module is production-ready and documented — not a roadmap feature or custom development engagement.

What should MedTech companies prioritize when selecting an EDC platform for Japan PMS?

MedTech companies managing Japan post-market surveillance studies should prioritize native Japan PMS functionality (booklet data, Kaifu workflows), PMDA ERES compliance documentation, study design flexibility for device-specific endpoints and variable follow-up schedules, and operational fit for lean clinical teams without dedicated EDC administrators. Evaluate whether the platform's licensing model (per-seat vs. study-based), study build approach (no-code vs. programmer-dependent), and support structure (24/7 vs. ticket-only) align with your team's capacity and budget constraints. Japan regulatory readiness and MedTech workflow adaptability should outweigh general enterprise EDC feature depth when the platform will primarily support focused post-market surveillance portfolios rather than large-scale pharma Phase III operations.

Making the right EDC platform choice for Japan post-market surveillance studies

The reviewed platforms span a wide capability range — from enterprise pharma systems designed for global Phase III operations to academic-focused tools built for cost-sensitive research environments. What they share is regulatory compliance for clinical data capture and monitoring; where they differ is the depth of Japan-specific PMS functionality, the operational model they assume, and the degree to which they treat medical device post-market surveillance as a supported workflow versus an edge case requiring custom development.

MedTech companies selecting EDC platforms for Japan post-market surveillance should match platform capability to operational profile: lean clinical teams with limited IT infrastructure benefit from no-code study design and study-based licensing rather than per-seat fees and programmer dependency; organizations managing both global trials and Japan PMS portfolios gain efficiency from unified eClinical suites with modular PMS functionality rather than separate vendor relationships for each study type; QA and regulatory teams prioritize platforms with documented PMDA ERES compliance and structured validation support over platforms requiring internal QA staff to fill regulatory gaps through custom documentation.

Platform selection for Japan PMS carries compounding consequences because validation burden, training investment, and vendor dependency accumulate across your device portfolio. Choose a platform that fits your operational reality from the start rather than forcing your team to work around limitations that were acceptable during initial evaluation but become operational friction as your Japan PMS portfolio scales.

Why Viedoc is the best EDC platform choice for Japan post-market surveillance studies

Viedoc's PMS solution is the only modular EDC platform with native Japan post-market surveillance functionality — booklet data collection, Kaifu process management, and progress tracking — built directly into the same no-code Designer environment used across 7,000+ global clinical studies in 75+ countries. The platform provides PMDA ERES compliance and APPI (Japan) data privacy certification with documented validation support, eliminating the gap-filling burden that lean MedTech QA teams face with platforms that treat Japan PMS as an afterthought. Viedoc's study-based licensing includes unlimited user seats with 24/7 support across global offices, so adding regional monitors or temporary study coordinators during high-enrollment periods doesn't trigger per-seat fees or force operational compromises.

Medical device companies using Viedoc for Japan PMS studies operate from a unified eClinical suite that handles EDC, ePRO, eTMF, and trial supply management with consistent user training, consolidated vendor management, and a single validation envelope — reducing total cost of ownership compared to multi-vendor stacks cobbled together to cover PMS requirements that weren't supported in the primary EDC. The no-code Designer capability extends to Japan PMS-specific workflows, so certified data managers configure booklet data CRFs and Kaifu review stages in-house without vendor programmer dependency or custom development timelines.

Viedoc is ISO 27001, ISO 9001, and SOC 2 Type II certified with FDA 21 CFR Part 11, ICH-GCP, EMA, GDPR, and HIPAA compliance, delivering 99.99% uptime on Microsoft Azure infrastructure with 40+ language support across global trials. The platform's track record includes 140,000+ users managing 1.6 million trial participants across 30,000+ sites, with established regulatory submission history and inspection readiness documentation structured for PMDA, FDA, and EMA audits.

If you're managing Japan post-market surveillance studies with lean clinical teams, device-specific regulatory requirements, and operational models where the same data manager designing the study is also running it and reporting on it, Viedoc delivers the Japan PMS functionality and lean-team operational fit that enterprise pharma platforms weren't designed to support. Book a demo or request a proposal and our team will walk you through booklet data configuration, Kaifu workflow management, and PMDA regulatory readiness in the context of your own device portfolio.